Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

Kiji Therapeutics Engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.

A new study in the peer-reviewed journal Stem Cells and Development highlights the potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) as a therapeutic strategy for high-dose ...